SANOFI US SERVICES INC.

Lobbying for SANOFI US SERVICES INC

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Expenses

$1,590,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 17

HR 7174
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 1503
Prescription Information Modernization Act of 2023
HR 2880
Protecting Patients Against PBM Abuses Act
HR 5376
Impacts and Outcomes for Health Career Training Act
HR 5539
ORPHAN Cures Act
HR 7834
Safe Cloud Storage Act
S 864
HELP Copays Act
S 1339
Pharmacy Benefit Manager Reform Act
S 1375
HELP Copays Act
S 1542
DRUG Act
S 2027
Prescription Information Modernization Act of 2025
S 4504
SCREEN for Type 1 Diabetes Act of 2024
HR 8698
SCREEN for Type 1 Diabetes Act of 2024
S 899
Producer and Agricultural Credit Enhancement Act of 2025
HR 3656
To amend the Agricultural Research, Extension, and Education Reform Act of 1998 to authorize the Secretary of Agricultu…
S 43
Skinny Labels, Big Savings Act

Lobbying activity 6

Manufacturing

Insulin; Taxes- General Issues; Vaccine - General Issues; Pharmacy Benefits Managers (PBMs); and Type 1 Diabetes Screening.

Health Issues

340B: Biologic/Small molecule drug negotiation eligibility within HR 7174; EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research Funding within LHHS appropriations; Delinking; Drug Price Negotiations within Inflation Reduction Act; Drug Pricing- General Issues; FDA Drug Development; FDA Issues - General; issues related to HR 1 One Big Beautiful Bill; HR 1503: Prescription Information Modernization Act of 2023; HR 2880: Protecting Patients Against PBM Abuses Act; HR 5376: Inflation Reduction Act; HRSA - Type 1 Diabetes Screening within LHHS appropriations; Influenza Vaccines; Insurance Design; Intellectual Property; International Reference Pricing; Most Favored Nation; Orphan Drug Negotiation within HR 5539/S 3131 Orphan Cures Act; Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization; Pharmacy Benefit Managers (PBM) Reform; Rare Pediatric Priority Review Voucher Program Reauthorization within HR 7834; Rebate Pass Through; Respiratory Syncytial Virus (RSV) Access; Routine Immunization Rates; S. 864 HELP Copays Act: S. 1339: PBM Reform Act; S. 1375 S. 1542: DRUG Act; S. 2027: Prescription Information Modernization Act; S.4504 / HR 8698 (118th): SCREEN for Type 1 Diabetes Act; Supply Chain; Tax Credits; Transplant; Vaccine Injury Compensation Program; Vaccines-General Issues.

Medicare/Medicaid

340B; Medicare Negotiation, and Most Favored Nation.

Trade (domestic/foreign)

Supply Chain Issues; and Importation issues.

Taxation/Internal Revenue Code

S. 899 One Big Beautiful Bill: BEAT, FDII, GILTI, and Tax Cuts and Job Acts; TRIP Waivers; HR 3656 (117th): Vaccine Injury Compensation Program.

S. 43: Skinny Labels, Big Savings Act; ETHIC Act; and Intellectual Property.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.